Clinical transplantation · 2026
Diagnostic Performance of Donor-derived Cell-free DNA Combined With Immune Activation Markers for Detecting Acute Rejection After Liver Transplantation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Xuechun, Yang Bo, Jiang Hongmei, Zhao Yuanyuan, Wei Lai, Chen Zhishui, Chen Dong
Аннотация
BACKGROUND: Accurate differentiation of acute rejection (AR) from other causes of graft dysfunction after liver transplantation remains challenging in real-world clinical practice. Although donor-derived cell-free DNA (dd-cfDNA) has emerged as a promising non-invasive biomarker of graft injury, its specificity may be limited in clinically suspected rejection due to concurrent inflammatory and non-rejection-related graft injuries. Immune activation markers may provide complementary information by reflecting ongoing alloimmune responses.
METHODS: In this prospective diagnostic study, we enrolled liver transplant recipients presenting with graft dysfunction and classified them as AR or non-rejection based on biopsy. Plasma dd-cfDNA levels and peripheral immune activation markers, including interleukin-2 receptor (IL-2R) and activated T-cell subsets, were measured. Diagnostic performance was evaluated using receiver operating characteristic analysis and multivariable models.
RESULTS: A total of 33 patients were included, comprising 18 with biopsy-proven AR and 15 with non-rejection graft dysfunction. dd-cfDNA levels were significantly higher in AR patients. Selected immune activation markers demonstrated complementary diagnostic characteristics. A simplified combined model integrating dd-cfDNA percentage with activated T-cell subsets achieved improved discrimination compared with individual markers. Decision curve analysis indicated a higher net clinical benefit across a range of threshold probabilities.
CONCLUSION: Integration of dd-cfDNA with immune activation markers provides a complementary non-invasive strategy for evaluating acute rejection in liver transplant recipients with clinically suspected graft dysfunction. This approach may improve real-world diagnostic assessment and assist clinical decision-making while reducing unnecessary liver biopsies.
METHODS: In this prospective diagnostic study, we enrolled liver transplant recipients presenting with graft dysfunction and classified them as AR or non-rejection based on biopsy. Plasma dd-cfDNA levels and peripheral immune activation markers, including interleukin-2 receptor (IL-2R) and activated T-cell subsets, were measured. Diagnostic performance was evaluated using receiver operating characteristic analysis and multivariable models.
RESULTS: A total of 33 patients were included, comprising 18 with biopsy-proven AR and 15 with non-rejection graft dysfunction. dd-cfDNA levels were significantly higher in AR patients. Selected immune activation markers demonstrated complementary diagnostic characteristics. A simplified combined model integrating dd-cfDNA percentage with activated T-cell subsets achieved improved discrimination compared with individual markers. Decision curve analysis indicated a higher net clinical benefit across a range of threshold probabilities.
CONCLUSION: Integration of dd-cfDNA with immune activation markers provides a complementary non-invasive strategy for evaluating acute rejection in liver transplant recipients with clinically suspected graft dysfunction. This approach may improve real-world diagnostic assessment and assist clinical decision-making while reducing unnecessary liver biopsies.